A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer

Annals of Oncology

Volumn 26, Issue 2, 2015, Pages 354-362

  Chiappori, Alberto A ^a   Kolevska, T ^b   Spigel, D R ^c   Hager, S ^d   Rarick, M ^b   Gadgeel, S ^e   Blais, N ^f   Von pawel, J ^g   Hart, L ^h   Reck, M ⁱ   Bassett, E ^j   Burington, B ^j   Schiller, J H ^k  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d Cancer Care Associates of Fresno   (United States)

^e KARMANOS CANCER INSTITUTE   (United States)

^f NOTRE DAME HOSPITAL   (Canada)

^g CHUM Hopital Notre Dame ^*  (Germany)

^h Sarah Cannon Florida Cancer Specialists   (United States)

ⁱ Airway Research Center North of the German Center for Lung Research (DZL)   (Germany)

^j GERON CORPORATION   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

Biomarker; Imetelstat; Non small cell lung cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; IMETELSTAT; TUMOR MARKER; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; INDOLE DERIVATIVE; NICOTINAMIDE; TELOMERASE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BACKACHE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; CORRELATIONAL STUDY; COUGHING; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTION; INFESTATION; LUNG HEMORRHAGE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NUTRITIONAL DISORDER; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SURVIVAL TIME; TELOMERE; TELOMERE LENGTH; THROMBOCYTOPENIA; TREND STUDY; VOMITING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INDOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NIACINAMIDE; PROPORTIONAL HAZARDS MODELS; TELOMERASE; TELOMERE;

EID: 84925341977     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu550     Document Type: Article

References (22)

1. McEachern MJ, Krauskopf A, Blackburn EH. Telomeres and their control. Annu Rev Genet 2000; 34: 331-358.
2. Harley CB. Telomerase is not an oncogene. Oncogene 2002; 21: 494-502.
3. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345: 458-460.
4. Harley CB, Sherwood SW. Telomerase, checkpoints and cancer. Cancer Surv 1997; 29: 263-284.
5. Asai A, Oshima Y, Yamamoto Y et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003; 63: 3931-3939.
6. Herbert BS, Gellert GC, Hochreiter A et al. Lipid modification of GRN163, an N30?P50 thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005; 24: 5262-5268.
7. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33: 787-791.
8. Herbert B, Pitts AE, Baker SI et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999; 96: 14276-14281.
9. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
10. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
11. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
12. Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-1234.
13. Zukin M, Barrios CH, Rodrigues Pereira J et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group Performance Status of 2. J Clin Oncol 2013; 31: 2849-2853.
14. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
15. Cappuzzo F, Ciuleanu T, Stelmakh L et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebocontrolled phase 3 study. Lancet Oncol 2010; 11: 521-529.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
17. National Cancer Institute. Common Terminology Criteria for Adverse Events v.4.0 (CTCAE). 2011. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
18. Johnson BE, Kris MG, Berry LD et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013; 31: (suppl; abstr 8019).
19. Joseph I, Tressler R, Bassett E et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010; 70: 9494-9504.
20. Castelo-Branco P, Zhang C, Lipman T et al. Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition. Clin Cancer Res 2011; 17: 111-121.
21. Johnson BE, Kabbinavar F, Fehrenbacher L et al. ATLAS: randomized, doubleblind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2013; 31: 3926-3934.
22. Patel JD, Socinski MA, Garon EB et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31: 4349-4357.